These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27885887)

  • 1. Cell therapies for Parkinson's disease: how far have we come?
    Stoker TB; Barker RA
    Regen Med; 2016 Dec; 11(8):777-786. PubMed ID: 27885887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD).
    Kirkeby A; Parmar M; Barker RA
    Prog Brain Res; 2017; 230():165-190. PubMed ID: 28552228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.
    Henchcliffe C; Sarva H
    CNS Drugs; 2020 Jun; 34(6):559-577. PubMed ID: 32472450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the clinical advancement of cell therapies for Parkinson's disease.
    Skidmore S; Barker RA
    Nat Biomed Eng; 2023 Apr; 7(4):370-386. PubMed ID: 36635420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, characterization, and banking of clinical-grade cells for neural transplantation: Scale up, fingerprinting, and genomic stability of stem cell lines.
    Natalwala A; Kunath T
    Prog Brain Res; 2017; 230():133-150. PubMed ID: 28552226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents.
    Niclis JC; Gantner CW; Alsanie WF; McDougall SJ; Bye CR; Elefanty AG; Stanley EG; Haynes JM; Pouton CW; Thompson LH; Parish CL
    Stem Cells Transl Med; 2017 Mar; 6(3):937-948. PubMed ID: 28297587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside.
    Wang M; Ling KH; Tan JJ; Lu CB
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease.
    Rodriguez-Pallares J; Rodriguez-Perez AI; Muñoz A; Parga JA; Toledo-Aral JJ; Labandeira-Garcia JL
    Stem Cells Transl Med; 2016 Jun; 5(6):804-15. PubMed ID: 27075764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural grafting for Parkinson's disease: challenges and prospects.
    Stoker TB; Blair NF; Barker RA
    Neural Regen Res; 2017 Mar; 12(3):389-392. PubMed ID: 28469646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing stem cell therapies for Parkinson's disease: waiting until the time is right.
    Barker RA
    Cell Stem Cell; 2014 Nov; 15(5):539-42. PubMed ID: 25517462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The science and ethics of cell-based therapies for Parkinson's disease.
    Towns CR
    Parkinsonism Relat Disord; 2017 Jan; 34():1-6. PubMed ID: 28341222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards stem cell based therapies for Parkinson's disease.
    Parmar M
    Development; 2018 Jan; 145(1):. PubMed ID: 29311261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses.
    Park TY; Jeon J; Cha Y; Kim KS
    Cell Res; 2024 Jul; 34(7):479-492. PubMed ID: 38777859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of cell therapies and brain repair: Parkinson's disease leads the way.
    Petit GH; Olsson TT; Brundin P
    Neuropathol Appl Neurobiol; 2014 Feb; 40(1):60-70. PubMed ID: 24372386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.
    Kriks S; Shim JW; Piao J; Ganat YM; Wakeman DR; Xie Z; Carrillo-Reid L; Auyeung G; Antonacci C; Buch A; Yang L; Beal MF; Surmeier DJ; Kordower JH; Tabar V; Studer L
    Nature; 2011 Nov; 480(7378):547-51. PubMed ID: 22056989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease.
    Grow DA; McCarrey JR; Navara CS
    Stem Cell Res; 2016 Sep; 17(2):352-366. PubMed ID: 27622596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic application of stem cell technology toward the treatment of Parkinson's disease.
    Nishimura K; Takahashi J
    Biol Pharm Bull; 2013; 36(2):171-5. PubMed ID: 23370347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for bringing stem cell-derived dopamine neurons to the clinic-The NYSTEM trial.
    Studer L
    Prog Brain Res; 2017; 230():191-212. PubMed ID: 28552229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.